Literature DB >> 23644662

Signaling through cyclin D-dependent kinases.

Y J Choi1, L Anders2.   

Abstract

Research over the past quarter century has identified cyclin D-dependent kinases, CDK4 and CDK6, as the major oncogenic drivers among members of the CDK superfamily. CDK4/6 are rendered hyperactive in the majority of human cancers through a multitude of genomic alterations. Sustained activation of these protein kinases provides cancer cells with the power to enter the cell cycle continuously by triggering G1-S-phase transitions and dramatically shortening the duration of the G1 phase. It has also become clear, however, that CDK4/6 effectively counter cancer cell-intrinsic tumor suppression mechanisms, senescence and apoptosis, which must be overcome during cell transformation and kept at bay throughout all stages of tumorigenesis. As a central 'node' in cellular signaling networks, cyclin D-dependent kinases sense a plethora of mitogenic signals to orchestrate specific transcriptional programs. As the complexity of the cellular signaling network regulated by these oncogenic kinases unfolds, much remains to be learned about its architecture, its dynamics and the consequences of its perturbation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23644662     DOI: 10.1038/onc.2013.137

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  102 in total

Review 1.  CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation.

Authors:  A-S Tigan; F Bellutti; K Kollmann; G Tebb; V Sexl
Journal:  Oncogene       Date:  2015-10-26       Impact factor: 9.867

Review 2.  Targeting CDK6 in cancer: State of the art and new insights.

Authors:  Solomon Tadesse; Mingfeng Yu; Malika Kumarasiri; Bich Thuy Le; Shudong Wang
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 3.  Clinical Trials in Non-Small Cell Lung Cancer with Biomarker-Driven Treatment Allocation: Ready or Not, Here We Come.

Authors:  Edward B Garon; Phillip A Abarca; Jennifer L Strunck; Danielle Nameth; Catherine Neumann; Brian Wolf; Kevin Y Kim; Caitlin Marx; Robert M Elashoff
Journal:  Crit Rev Oncog       Date:  2015

4.  CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma.

Authors:  Mary E Olanich; Wenyue Sun; Stephen M Hewitt; Zied Abdullaev; Svetlana D Pack; Frederic G Barr
Journal:  Clin Cancer Res       Date:  2015-03-25       Impact factor: 12.531

Review 5.  Therapeutic Implications of the Genetic Landscape of Head and Neck Cancer.

Authors:  Janice Cho; Daniel E Johnson; Jennifer R Grandis
Journal:  Semin Radiat Oncol       Date:  2018-01       Impact factor: 5.934

6.  Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance.

Authors:  James L Chen; Tanios Bekaii-Saab; Daniel H Ahn; Milind Javle; Chul W Ahn; Apurva Jain; Sameh Mikhail; Anne M Noonan; Kristen Ciombor; Christina Wu; Rachna T Shroff
Journal:  Cancer       Date:  2016-08-06       Impact factor: 6.860

7.  Aberrant expression of cyclin D1 in cancer.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Sign Transduct Insights       Date:  2015-09-20

8.  The Notch pathway regulates the Second Mitotic Wave cell cycle independently of bHLH proteins.

Authors:  Abhishek Bhattacharya; Ke Li; Manon Quiquand; Gerard Rimesso; Nicholas E Baker
Journal:  Dev Biol       Date:  2017-09-14       Impact factor: 3.582

9.  Chemoproteomic Profiling Uncovers CDK4-Mediated Phosphorylation of the Translational Suppressor 4E-BP1.

Authors:  Dylan C Mitchell; Arya Menon; Amanda L Garner
Journal:  Cell Chem Biol       Date:  2019-05-02       Impact factor: 8.116

10.  The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes.

Authors:  Sabine Paternot; Bianca Colleoni; Xavier Bisteau; Pierre P Roger
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.